COPN — Cosmo Pharmaceuticals NV Share Price
Last trade - 00:00- CH₣890.99m
- CH₣780.46m
- €266.79m
- 88
- 44
- 26
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.7 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -37.23% | ||
| Dividend Yield (f) | 3.92% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.05 | ||
| Price to Tang. Book | 8.82 | ||
| Price to Free Cashflow | 14.15 | ||
| Price to Sales | 5.18 | ||
| EV to EBITDA | 11.53 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.78% | ||
| Return on Equity | 11.52% | ||
| Operating Margin | 33.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 60.95 | 65.07 | 102.09 | 92.78 | 266.79 | 149 | 181 | 33.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -18.2 | n/a | n/a | -74.72 | +51.87 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.
Directors
- Mauro Ajani NEC (66)
- Alessandro Della Cha CEO (58)
- Niall Donnelly CFO (46)
- Marco Lecchi COO (57)
- Stefano Selva CSO
- H. Jurgen Lenz OTH (68)
- Luisa Bartorelli MGB (49)
- Roberta Bozzella MGB (47)
- Andrea Cherubini MGB (48)
- Giulio Evangelisti MGB (51)
- Andrea Lovati MGB (54)
- Sean Macdonald MGB (45)
- Davide Malavasi MGB (49)
- Nhan Ngo Dinh MGB (42)
- Massimo Pedrani MGB (67)
- Roberto Villa MGB (78)
- Eimear Cowhey NED (55)
- Kevin Donovan NED (62)
- Dieter A. Enkelmann NED (62)
- Maria Roncarolo NED (67)
- Hans Tanner NED (70)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- January 1st, 1970
- Public Since
- May 18th, 2016
- No. of Employees
- 332
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 15,938,925
- Address
- Riverside II, Sir John Rogerson's Quay, DUBLIN
- Web
- https://www.cosmopharma.com/
- Phone
- +353 18170370
- Auditors
- Deloitte Accountants B.V.
Upcoming Events for COPN
Similar to COPN
Curatis Holding AG
SIX Swiss Exchange
Dottikon ES Holding AG
SIX Swiss Exchange
Galenica AG
SIX Swiss Exchange
Novartis AG
SIX Swiss Exchange
PolyPeptide AG
SIX Swiss Exchange
FAQ
As of Today at 20:04 UTC, shares in Cosmo Pharmaceuticals NV are trading at CH₣55.90. This share price information is delayed by 15 minutes.
Shares in Cosmo Pharmaceuticals NV last closed at CH₣55.90 and the price had moved by -28.85% over the past 365 days. In terms of relative price strength the Cosmo Pharmaceuticals NV share price has underperformed the FTSE Global All Cap Index by -34.19% over the past year.
The overall consensus recommendation for Cosmo Pharmaceuticals NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Cosmo Pharmaceuticals NV dividend yield is 3.46% based on the trailing twelve month period.
Last year, Cosmo Pharmaceuticals NV paid a total dividend of €2.05, and it currently has a trailing dividend yield of 3.46%. We do not have any data on when Cosmo Pharmaceuticals NV is to next pay dividends.
We do not have data on when Cosmo Pharmaceuticals NV is to next pay dividends. The historic dividend yield on Cosmo Pharmaceuticals NV shares is currently 3.46%.
To buy shares in Cosmo Pharmaceuticals NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣55.90, shares in Cosmo Pharmaceuticals NV had a market capitalisation of CH₣890.99m.
Here are the trading details for Cosmo Pharmaceuticals NV:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: COPN
Based on an overall assessment of its quality, value and momentum Cosmo Pharmaceuticals NV is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cosmo Pharmaceuticals NV is CH₣99.50. That is 78% above the last closing price of CH₣55.90.
Analysts covering Cosmo Pharmaceuticals NV currently have a consensus Earnings Per Share (EPS) forecast of €2.06 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cosmo Pharmaceuticals NV. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -12.88%.
As of the last closing price of CH₣55.90, shares in Cosmo Pharmaceuticals NV were trading -5.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cosmo Pharmaceuticals NV PE ratio based on its reported earnings over the past 12 months is 21.7. The shares last closed at CH₣55.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cosmo Pharmaceuticals NV's management team is headed by:
- Mauro Ajani - NEC
- Alessandro Della Cha - CEO
- Niall Donnelly - CFO
- Marco Lecchi - COO
- Stefano Selva - CSO
- H. Jurgen Lenz - OTH
- Luisa Bartorelli - MGB
- Roberta Bozzella - MGB
- Andrea Cherubini - MGB
- Giulio Evangelisti - MGB
- Andrea Lovati - MGB
- Sean Macdonald - MGB
- Davide Malavasi - MGB
- Nhan Ngo Dinh - MGB
- Massimo Pedrani - MGB
- Roberto Villa - MGB
- Eimear Cowhey - NED
- Kevin Donovan - NED
- Dieter A. Enkelmann - NED
- Maria Roncarolo - NED
- Hans Tanner - NED